Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial

Higgins et al., JAMA, doi:10.1001/jama.2022.23257, REMAP-CAP, NCT02735707 (history)

Higgins et al., Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical.., JAMA, doi:10.1001/jama.2022.23257, REMAP-CAP, NCT02735707

Dec 2022 Source PDF

Twitter
Facebook

All Studies Meta

Long-term followup for the REMAP-CAP very late stage ICU trial, showing higher risk with HCQ, not quite reaching statistical significance.

Important missing comments or errors? Let us know.

This study includes convalescent plasma and HCQ.

risk of death, 51.0% higher, HR 1.51, p = 0.06, treatment 16 of 41 (39.0%), control 107 of 311 (34.4%), adjusted per study, day 180.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Higgins et al., 16 Dec 2022, Randomized Controlled Trial, multiple countries, peer-reviewed, 1896 authors, study period 9 March, 2020 - 22 June, 2021, trial NCT02735707 (history) (REMAP-CAP).

All Studies Meta Analysis Submit Updates or Corrections

This Paper HCQ All

Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial

Simin Florescu, Delia Stanciu, Mihaela Zaharia, Alma Kosa, Daniel Codreanu, Aneela Kidwai, Sobia Masood, Callum Kaye, Amanda Coutts, Lynn Mackay, Charlotte Summers, Petra Polgarova, Neda Farahi, Eleonore Fox, Stephen Mcwilliam, Daniel Hawcutt, Laura Rad, Laura O’malley, Jennifer Whitbread, Dawn Jones, Rachael Dore, Paula Saunderson, Olivia Kelsall, Nicholas Cowley, Laura Wild, Jessica Thrush, Hannah Wood, Karen Austin, János Bélteczki, István Magyar, Ágnes Fazekas, Sándor Kovács, Viktória Szőke, Adrian Donnelly, Martin Kelly, Naoise Smyth, Sinéad O’kane, Declan Mcclintock, Majella Warnock, Ryan Campbell, Edmund Mccallion, Amine azaiz, Cyril Charron, Mathieu Godement, Guillaume Geri, Antoine Vieillard-Baron, Paul Johnson, Shirley Mckenna, Joanne Hanley, Andrew Currie, Barbara Allen, Clare Mcgoldrick, Moyra Mcmaster, Ashwin Mani, Meghena Mathew, Revathi Kandeepan, C Vignesh, Bharath Tv, N Ramakrishnan, Augustian James, Evangeline Elvira, Devachandran Jayakumar, Ramachandran Pratheema, Suresh Babu, R Ebenezer, S Krishnaoorthy, Lakshmi Ranganathan, Manisha Ganesan, Madhu Shree, Eileen Guilder, Magdalena Butler, Keri-Anne Cowdrey, Melissa Robertson, Farisha Ali, Ellie Mcmahon, Eamon Duffy, Yan Chen, Catherine Simmonds, Rachael Mcconnochie, Caroline O’connor, Khaled El-Khawas, Angus Richardson, Dianne Hill, Robert Commons, Hussam Abdelkharim, Manoj Saxena, Margaret Muteithia, Kelsey Dobell-Brown, Rajeev Jha, Michael Kalogirou, Christine Ellis, Vinodh Krishnamurthy, Aibhilin O’connor, Saranya Thurairatnam, Dipak Mukherjee, Agilan Kaliappan, Mark Vertue, Anne Nicholson, Joanne Riches, Gracie Maloney, Lauren Kittridge, Amanda Solesbury, Angelo Ramos, Daniel Collins, Kathy Brickell, Liadain Reid, Michelle Smyth, Patrick Breen, Sandra Spain, Gerard Curley, Natalie Mcevoy, Pierce Geoghegan, Jennifer Clarke, Jon Silversides, Peter Mcguigan, Kathryn Ward, Aisling O’neill, Stephanie Finn, Chris Wright, Jackie Green, Érin Collins, Cameron Knott, Julie Smith, Catherine Boschert, Kitty Slieker, Esther Ewalds, Arnate Sanders, Wendy Wittenberg, Heidi Geurts, Latesh Poojara, Treena Sara, Kiran Nand, Brenda Reeve, William Dechert, Barbara Phillips, Laura Oritz-Ruiz De gordoa, Julia Affleck, Arif Shaikh, Andrew Murray, Mahesh Ramanan, Thuy Frakking, Jez Pinnell, Matt Robinson, Lisa Gledhill, Tracy Wood, Ritesh Sanghavi, Deepak Bhonagiri, Megan Ford, Harshel G Parikh, Bronwyn Avard, Mary Nourse, Bree Mcdonald, Natasha Edmunds, Oscar Hoiting, Marco Peters, Els Rengers, Mirjam Evers, Anton Prinssen, Matt Morgan, Jade Cole, Helen Hill, Michelle Davies, Angharad Williams, Emma Thomas, Rhys Davies, Matt Wise, Patrick Grimm, Jens Soukup, Richard Wetzold, Madlen Löbel, Lisa Starke, Francois Lellouche, Patricia Lizotte, Pierre Declerq, Marchalot Antoine, Gelinotte Stephanie, Eraldi Jean-Pierre, Bourgerol François, Beuzelin Marion, Rigaud Philippe, Franck Pourcine, Mehran Monchi, David Luis, Romain Mercier, Anne Sagnier, Nathalie Verrier, Cecile Caplin, Jack Richecoeu, Daniele Combaux, Shidasp Siami, Christelle Aparicio, Sarah Vautier, Asma Jeblaoui, Delphine Lemaire-Brunel, Frédérick D'aragon, Elaine Carbonneau, Julie Leblond, Gaetan Plantefeve, Cécile Leparco, Damien Contou, Muriel Fartoukh, Laura Courtin, Vincent Labbe, Guillaume Voiriot, Sara Salhi, Michaël Chassé, François Carrier, Dounia Boumahni, Fatna Benettaib, Ali Ghamraoui, Arnaud Sement, Alexandre Gachet, Alexis Hanisch, Abdelmagid Haffiane, Anne-Hélène Boivin, Amelie Barreau, Elodie Guerineau, Séverine Poupblanc, Pierre Egreteau, Montaine Lefevre, Simon Bocher, Guillaume Le Loup, Lenaïg Le Guen, Vanessa Carn, Melanie Bertel, David Antcliffe, Maie Templeton, Roceld Rojo, Phoebe Coghlan, Joanna Smee, Gareth Barker, André Finn, Gabriele Kreb, Uwe Hoff, Carl Hinrichs, Jens Nee, Euan Mackay, Jon Cort, Amanda Whileman, Thomas Spencer, Nick Spittle, Sarah Beavis, Anand Padmakumar, Katie Dale, Joanne Hawes, Emma Moakes, Rachel Gascoyne, Kelly Pritchard, Lesley Stevenson, Justin Cooke

JAMA, doi:10.1001/jama.2022.23257

Writing Committee for the REMAP-CAP Investigators IMPORTANCE The longer-term effects of therapies for the treatment of critically ill patients with COVID-19 are unknown. OBJECTIVE To determine the effect of multiple interventions for critically ill adults with COVID-19 on longer-term outcomes. DESIGN, SETTING, AND PARTICIPANTS Prespecified secondary analysis of an ongoing adaptive platform trial (REMAP-CAP) testing interventions within multiple therapeutic domains in which 4869 critically ill adult patients with COVID-19 were enrolled between March 9, 2020, and June 22, 2021, from 197 sites in 14 countries. The final 180-day follow-up was completed on March 2, 2022. INTERVENTIONS Patients were randomized to receive 1 or more interventions within 6 treatment domains: immune modulators (n = 2274), convalescent plasma (n = 2011), antiplatelet therapy (n = 1557), anticoagulation (n = 1033), antivirals (n = 726), and corticosteroids (n = 401). MAIN OUTCOMES AND MEASURES The main outcome was survival through day 180, analyzed using a bayesian piecewise exponential model. A hazard ratio (HR) less than 1 represented improved survival (superiority), while an HR greater than 1 represented worsened survival (harm); futility was represented by a relative improvement less than 20% in outcome, shown by an HR greater than 0.83. RESULTS Among 4869 randomized patients (mean age, 59.3 years; 1537 [32.1%] women), 4107 (84.3%) had known vital status and 2590 (63.1%) were alive at day 180. IL-6 receptor antagonists had a greater than 99.9% probability of improving 6-month survival (adjusted HR, 0.74 [95% credible interval {CrI}, 0.61-0.90]) and antiplatelet agents had a 95% probability of improving 6-month survival (adjusted HR, 0.85 [95% CrI, 0.71-1.03]) compared with the control, while the probability of trial-defined statistical futility (HR >0.83) was high for therapeutic anticoagulation (99.9%; HR, 1.13 [95% CrI, 0.93-1.42]), convalescent plasma (99.2%; HR, 0.99 [95% CrI, 0.86-1.14]), and lopinavir-ritonavir (96.6%; HR, 1.06 [95% CrI, 0.82-1.38]) and the probabilities of harm from hydroxychloroquine (96.9%; HR, 1.51 [95% CrI, 0.98-2.29]) and the combination of lopinavir-ritonavir and hydroxychloroquine (96.8%; HR, 1.61 [95% CrI, 0.97-2.67]) were high. The corticosteroid domain was stopped early prior to reaching a predefined statistical trigger; there was a 57.1% to 61.6% probability of improving 6-month survival across varying hydrocortisone dosing strategies. CONCLUSIONS AND RELEVANCE Among critically ill patients with COVID-19 randomized to receive 1 or more therapeutic interventions, treatment with an IL-6 receptor antagonist had a greater than 99.9% probability of improved 180-day mortality compared with patients randomized to the control, and treatment with an antiplatelet had a 95.0% probability of improved 180-day mortality compared with patients randomized to the control. Overall, when considered with previously reported short-term results, the..

Author Contributions: Dr Higgins had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Drs Webb, Lawler, and Gordon contributed equally as co-senior authors. Concept and design: Higgins, L. Berry, Lorenzi, Murthy, McQuilten, Bentum-Puijk, Bonten, Bradbury, Burrell, Girard, Goossens, Hills, McAuley, Neal, Parke, Parker, Rowan, Shankar-Hari, Turgeon, van Additional Contributions: We are grateful to the NIHR Clinical Research Network (UK), UPMC Health System Health Services Division (US), and the Direction de la Recherche Clinique et de l'Innovation de l'AP-HP (France) for their support of participant recruitment. We are also very thankful to the patients who have participated in this trial.

References

Al-Beidh, Phd; Djillali Annane, Phd; Yaseen, Arabi, Md, None

Alistair, Nichol, Md, Phd, Rachael et al., None

Angus, Berry, Lewis, The REMAP-CAP (randomized embedded multifactorial adaptive platform for community-acquired pneumonia) study: rationale and design, Ann Am Thorac Soc, doi:10.1513/AnnalsATS.202003-192SD

Angus, Derde, Al-Beidh, Writing Committee for the REMAP-CAP Investigators. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial, JAMA, doi:10.1001/jama.2020.17022?utm_campaign=articlePDF%26utm_medium=articlePDFlink%26utm_source=articlePDF%26utm_content=jama.2022.23257

Angus, Md, Mph, None

Arabi, Gordon, Derde, Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial, Intensive Care Med, doi:10.1007/s00134-021-06448-5

Attacc Investigators, Therapeutic anticoagulation with heparin in critically ill patients with Covid-19

Auriemma, Harhay, Haines, Barg, Halpern et al., What matters to patients and their families during and after critical illness: a qualitative study, Am J Crit Care, doi:10.4037/ajcc2021398

Beane, None

Berry, None

Berry, None, PhD

Bhimani, Mph, None

Bradbury, Lawler, Stanworth, REMAP-CAP Writing Committee for the REMAP-CAP Investigators. Effect of antiplatelet therapy on survival and organ support-free days in critically ill patients with COVID-19: a randomized clinical trial, JAMA, doi:10.1001/jama.2022.2910?utm_campaign=articlePDF%26utm_medium=articlePDFlink%26utm_source=articlePDF%26utm_content=jama.2022.23257

Bradbury, Md, None

Brown, Wilson, Presson, the National Institutes of Health NHLBI ARDS Network. Predictors of 6-month health utility outcomes in survivors of acute respiratory distress syndrome, Thorax, doi:10.1136/thoraxjnl-2016-208560

Burrell, Mbbs, None

Buxton, None

Buzgau, None, MSc

Charles, Mbbs, None

Christopher, Horvat, Md, None

Consultants, Austin, Texas, Berry, Lorenzi et al., None

Cove, Mbbs, None

Critical, Group, Functional disability 5 years after acute respiratory distress syndrome, N Engl J Med, doi:10.1056/NEJMoa1011802

Critical, Group, One-year outcomes in survivors of the acute respiratory distress syndrome, N Engl J Med, doi:10.1056/NEJMoa022450

Daniel, Mcauley, Md, None

David, None

Derde, Webb, Lawler, Higgins, Berry et al., Critical revision of the manuscript for important intellectual content

Detry, None, PhD

Dolan, Gudex, Kind, Williams, A Social Tariff for EuroQol: Results from a UK General Population Survey

Estcourt, Mbbch, None

Estcourt, Turgeon, Mcquilten, Writing Committee for the REMAP-CAP Investigators. Effect of convalescent plasma on organ support-free days in critically ill patients with covid-19: a randomized clinical trial, JAMA, doi:10.1001/jama.2021.18178?utm_campaign=articlePDF%26utm_medium=articlePDFlink%26utm_source=articlePDF%26utm_content=jama.2022.23257

Fagbodun, None, MSc

Fitzgerald, None

Frank, Brunkhorst, Md, None

Frank, Van De Veerdonk, Md, None

Gaudry, Messika, Ricard, Patient-important outcomes in randomized controlled trials in critically ill patients: a systematic review, Ann Intensive Care, doi:10.1186/s13613-017-0243-z

Girard, Md, Msci, None

Goligher, Bradbury, Mcverry, REMAP-CAP Investigators

Goligher, Md, None

Goossens, Phd, None

Gordon, Mouncey, Al-Beidh, Interleukin-6 receptor antagonists in critically ill patients with Covid-19

Green, None, MSc

Group, EuroQol: a new facility for the measurement of health-related quality of life, Health Policy, doi:10.1016/0168-8510(90)90421-9

Haniffa, Phd, Hills, Mbbs, None

Hashem, Nallagangula, Nalamalapu, Patient outcomes after critical illness: a systematic review of qualitative studies following hospital discharge, Crit Care, doi:10.1186/s13054-016-1516-x

Herdman, Gudex, Lloyd, Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L), Qual Life Res, doi:10.1007/s11136-011-9903-x

Herridge, Cheung, Tansey, None

Herridge, Tansey, Matté, None

Higgins, Neto, Bailey, Investigators. Predictors of death and new disability after critical illness: a multicentre prospective cohort study, Intensive Care Med, doi:10.1007/s00134-021-06438-7

Higgins, Neto, Bailey, The psychometric properties and minimal clinically important difference for disability assessment using WHODAS 2.0 in critically ill patients, Crit Care and Resuscitation, doi:10.51893/2021.1.oa10

Hodgson, Higgins, Bailey, COVID-Recovery Study Investigators and the ANZICS Clinical Trials Group. Comparison of 6-month outcomes of survivors of COVID-19 versus non-COVID-19 critical illness, Am J Respir Crit Care Med, doi:10.1164/rccm.202110-2335OC

Huang, Mph, None

Ichihara, Md, Mph, None

Kosyakovsky, Angriman, Katz, Association between sepsis survivorship and long-term cardiovascular outcomes in adults: a systematic review and meta-analysis, Intensive Care Med, doi:10.1007/s00134-021-06479-y

Lamontagne, Md, None

Lennie, Derde, Md, Phd, Anthony et al., None

Lewis, Md, None

Loo, Scholle Of Medicine, None

Lorenzi, Phd, None

Marc, Bonten, Md, None

Marshall, Md, None

Mcarthur, Md, None

Mcglothlin, Phd, None

Mcpeake, Shaw, Mactavish, Long-term outcomes following severe COVID-19 infection: a propensity matched cohort study, BMJ Open Respir Res, doi:10.1136/bmjresp-2021-001080

Mcquilten, Phd, None

Mcverry, Md, None

Munk, None

Murthy, Md, None

Neal, Md, None

Pallanch, Ortalda, Pelosi, Effects on health-related quality of life of interventions affecting survival in critically ill patients: a systematic review, Crit Care, doi:10.1186/s13054-022-03993-3

Parker, Bn, None

Parry-Billings, None, MSc

Patrick, Lawler, Affiliations of Authors/Members of the Writing Committee for the REMAP-CAP Investigators: Monash University

Paul, Mouncey, None, MSc

Prescott, Angus, Enhancing recovery from sepsis: a review, JAMA, doi:10.1001/jama.2017.17687?utm_campaign=articlePDF%26utm_medium=articlePDFlink%26utm_source=articlePDF%26utm_content=jama.2022.23257

Prescott, Osterholzer, Langa, Angus, Iwashyna, Late mortality after sepsis: propensity matched cohort study, BMJ, doi:10.1136/bmj.i2375

Rowan, Saito, Mph, None

Sam, Peters, Barch, Luis, Reyes et al., None

Santos, Saunders, Serpa-Neto, Phd, Msc et al., None

Saud Bin Abdulaziz, None

Seymour, Md, None

Shankar-Hari, Md, None

Shankar-Hari, Saha, Wilson, Rate and risk factors for rehospitalisation in sepsis survivors: systematic review and meta-analysis, Intensive Care Med, doi:10.1007/s00134-019-05908-3

Shay, Mcguinness, Md, None

Stronach, None, BSc

Turgeon, Md, None

Turner, None

Ustun, Kostanjesek, Chatterji, Rehm, Measuring Health and Disability: Manual for WHO Disability Assessment Schedule (WHODAS 2.0

Ustün, Chatterji, Kostanjsek, None

Van Bentum-Puijk, None, MSc

Webb, Md, None

Weihe, Mortensen, Haase, Long-term cognitive and functional status in Danish ICU patients with COVID-19, Acta Anaesthesiol Scand, doi:10.1111/aas.14108

Zarychanski, Md, None

Late treatment
is less effective

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit